Cardiac glycosides and their aglycone derivatives treat complications of diabetes
AssigneeThe Scripps Research Institute
InventorRobert Z. Florkiewicz
Life of this patent
Estimating the term…
Abstract
This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1α, IL-1β and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.
Claims7
A method of treating complications of diabetes, comprising contacting a cell exporting FGF or other leaderless protein with a therapeutically effective amount of a cardiac glycoside.
A method of treating complications of diabetes, comprising contacting a cell exporting FGF or other leaderless protein with a therapeutically effective amount of an aglycone derivative of a cardiac glycoside.
Dependencies are inferred from the claim text.